vs

Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and ROYAL GOLD INC (RGLD). Click either name above to swap in a different company.

EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $375.3M, roughly 1.6× ROYAL GOLD INC). EXELIXIS, INC. runs the higher net margin — 40.8% vs 24.9%, a 15.9% gap on every dollar of revenue. On growth, ROYAL GOLD INC posted the faster year-over-year revenue change (85.3% vs 5.6%). Over the past eight quarters, ROYAL GOLD INC's revenue compounded faster (58.8% CAGR vs 18.7%).

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Royal Gold Inc. is a leading precious metals streaming and royalty firm that acquires and manages a diversified portfolio of streaming interests, royalties, and equity interests tied to mining projects. Its assets cover gold, silver, and copper production across North America, South America, Africa, and Australia, operating with a low-risk model that avoids direct mining operations.

EXEL vs RGLD — Head-to-Head

Bigger by revenue
EXEL
EXEL
1.6× larger
EXEL
$598.7M
$375.3M
RGLD
Growing faster (revenue YoY)
RGLD
RGLD
+79.7% gap
RGLD
85.3%
5.6%
EXEL
Higher net margin
EXEL
EXEL
15.9% more per $
EXEL
40.8%
24.9%
RGLD
Faster 2-yr revenue CAGR
RGLD
RGLD
Annualised
RGLD
58.8%
18.7%
EXEL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EXEL
EXEL
RGLD
RGLD
Revenue
$598.7M
$375.3M
Net Profit
$244.5M
$93.6M
Gross Margin
95.6%
64.6%
Operating Margin
39.3%
56.2%
Net Margin
40.8%
24.9%
Revenue YoY
5.6%
85.3%
Net Profit YoY
74.8%
-12.8%
EPS (diluted)
$0.89
$1.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXEL
EXEL
RGLD
RGLD
Q1 26
$598.7M
Q4 25
$597.8M
$375.3M
Q3 25
$568.3M
$252.1M
Q2 25
$555.4M
$209.6M
Q1 25
$566.8M
$193.4M
Q4 24
$202.6M
Q3 24
$539.5M
$193.8M
Q2 24
$637.2M
$174.1M
Net Profit
EXEL
EXEL
RGLD
RGLD
Q1 26
$244.5M
Q4 25
$193.6M
$93.6M
Q3 25
$184.8M
$126.8M
Q2 25
$159.6M
$132.3M
Q1 25
$139.9M
$113.5M
Q4 24
$107.4M
Q3 24
$118.0M
$96.2M
Q2 24
$226.1M
$81.2M
Gross Margin
EXEL
EXEL
RGLD
RGLD
Q1 26
95.6%
Q4 25
96.9%
64.6%
Q3 25
96.6%
73.6%
Q2 25
96.5%
72.6%
Q1 25
96.5%
69.4%
Q4 24
70.3%
Q3 24
96.8%
66.6%
Q2 24
97.2%
64.7%
Operating Margin
EXEL
EXEL
RGLD
RGLD
Q1 26
39.3%
Q4 25
39.6%
56.2%
Q3 25
37.6%
64.4%
Q2 25
33.6%
67.7%
Q1 25
28.8%
63.6%
Q4 24
65.9%
Q3 24
25.2%
61.3%
Q2 24
43.3%
58.6%
Net Margin
EXEL
EXEL
RGLD
RGLD
Q1 26
40.8%
Q4 25
32.4%
24.9%
Q3 25
32.5%
50.3%
Q2 25
28.7%
63.1%
Q1 25
24.7%
58.7%
Q4 24
53.0%
Q3 24
21.9%
49.7%
Q2 24
35.5%
46.6%
EPS (diluted)
EXEL
EXEL
RGLD
RGLD
Q1 26
$0.89
Q4 25
$0.69
$1.04
Q3 25
$0.65
$1.92
Q2 25
$0.55
$2.01
Q1 25
$0.47
$1.72
Q4 24
$1.63
Q3 24
$0.40
$1.46
Q2 24
$0.77
$1.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXEL
EXEL
RGLD
RGLD
Cash + ST InvestmentsLiquidity on hand
$1.1B
$233.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.2B
$7.2B
Total Assets
$2.8B
$9.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXEL
EXEL
RGLD
RGLD
Q1 26
$1.1B
Q4 25
$988.5M
$233.7M
Q3 25
$791.1M
$172.8M
Q2 25
$1.0B
$248.2M
Q1 25
$1.1B
$240.8M
Q4 24
$195.5M
Q3 24
$1.2B
$127.9M
Q2 24
$1.0B
$74.2M
Total Debt
EXEL
EXEL
RGLD
RGLD
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$0
Q2 24
$50.0M
Stockholders' Equity
EXEL
EXEL
RGLD
RGLD
Q1 26
$2.2B
Q4 25
$2.2B
$7.2B
Q3 25
$2.0B
$3.4B
Q2 25
$2.1B
$3.3B
Q1 25
$2.2B
$3.2B
Q4 24
$3.1B
Q3 24
$2.3B
$3.0B
Q2 24
$2.1B
$3.0B
Total Assets
EXEL
EXEL
RGLD
RGLD
Q1 26
$2.8B
Q4 25
$2.8B
$9.5B
Q3 25
$2.7B
$4.5B
Q2 25
$2.8B
$3.6B
Q1 25
$2.9B
$3.5B
Q4 24
$3.4B
Q3 24
$3.0B
$3.3B
Q2 24
$2.8B
$3.3B
Debt / Equity
EXEL
EXEL
RGLD
RGLD
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXEL
EXEL
RGLD
RGLD
Operating Cash FlowLast quarter
$333.5M
$241.7M
Free Cash FlowOCF − Capex
$332.4M
FCF MarginFCF / Revenue
55.5%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
1.36×
2.58×
TTM Free Cash FlowTrailing 4 quarters
$875.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXEL
EXEL
RGLD
RGLD
Q1 26
$333.5M
Q4 25
$290.3M
$241.7M
Q3 25
$49.0M
$174.0M
Q2 25
$211.4M
$152.8M
Q1 25
$240.3M
$136.4M
Q4 24
$141.1M
Q3 24
$271.3M
$136.7M
Q2 24
$119.5M
$113.5M
Free Cash Flow
EXEL
EXEL
RGLD
RGLD
Q1 26
$332.4M
Q4 25
$288.8M
Q3 25
$46.2M
Q2 25
$208.5M
Q1 25
$236.3M
Q4 24
Q3 24
$263.1M
Q2 24
$113.0M
FCF Margin
EXEL
EXEL
RGLD
RGLD
Q1 26
55.5%
Q4 25
48.3%
Q3 25
8.1%
Q2 25
37.5%
Q1 25
41.7%
Q4 24
Q3 24
48.8%
Q2 24
17.7%
Capex Intensity
EXEL
EXEL
RGLD
RGLD
Q1 26
0.2%
Q4 25
0.2%
Q3 25
0.5%
Q2 25
0.5%
Q1 25
0.7%
Q4 24
Q3 24
1.5%
Q2 24
1.0%
Cash Conversion
EXEL
EXEL
RGLD
RGLD
Q1 26
1.36×
Q4 25
1.50×
2.58×
Q3 25
0.27×
1.37×
Q2 25
1.32×
1.15×
Q1 25
1.72×
1.20×
Q4 24
1.31×
Q3 24
2.30×
1.42×
Q2 24
0.53×
1.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXEL
EXEL

Cabometyx$544.7M91%
Collaboration$52.1M9%
Collaborative Arrangementwith Takeda$5.9M1%
Cometriq$1.8M0%

RGLD
RGLD

Gold$216.9M58%
Pueblo Viejo$47.3M13%
Andacollo$32.6M9%
Silver$32.1M9%
Other$27.2M7%
Copper$13.7M4%
Cortez Legacy Zone$5.4M1%

Related Comparisons